002603 以岭药业
已收盘 07-03 15:00:00
资讯
新帖
简况
以岭药业（002603）股东吴相君质押80万股，占总股本0.05%
证券之星 · 06-21
以岭药业（002603）股东吴相君质押80万股，占总股本0.05%
以岭药业：我们会及时反馈至公司管理层及电商部门参考
证券之星 · 06-21
以岭药业：我们会及时反馈至公司管理层及电商部门参考
以岭药业新提交1件商标注册申请
证券之星 · 06-17
以岭药业新提交1件商标注册申请
以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理
证券之星 · 06-13
以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理
以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理
智通财经 · 06-13
以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理
重磅！以岭药业创新中药治疗早衰研究取得重大突破
证券之星 · 06-05
重磅！以岭药业创新中药治疗早衰研究取得重大突破
以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权
证券之星 · 06-02
以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权
以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单
证券之星 · 05-29
以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单
[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列
证券之星 · 05-22
[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列
以岭药业（002603）5月16日主力资金净卖出5918.49万元
证券之星 · 05-17
以岭药业（002603）5月16日主力资金净卖出5918.49万元
世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章
证券之星 · 05-14
世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章
向世界讲好中医药故事，以岭药业荣获“品牌创新先锋企业”称号
证券之星 · 05-13
向世界讲好中医药故事，以岭药业荣获“品牌创新先锋企业”称号
以岭药业：创新中药 助力构建人类卫生健康共同体
证券之星 · 05-09
以岭药业：创新中药 助力构建人类卫生健康共同体
以岭药业：后续如有达到信披标准的事项，公司会积极履行信息披露义务
证券之星 · 05-08
以岭药业：后续如有达到信披标准的事项，公司会积极履行信息披露义务
以岭药业获信达证券增持评级，推动新药研发
金融界 · 04-30
以岭药业获信达证券增持评级，推动新药研发
以岭药业非呼吸系统类产品营收创历史新高 中医药临床循证研究筑牢科技核心竞争力
新浪证券 · 04-29
以岭药业非呼吸系统类产品营收创历史新高 中医药临床循证研究筑牢科技核心竞争力
以岭药业：4月28日召开业绩说明会，华创证券、华福证券等多家机构参与
证券之星 · 04-28
以岭药业：4月28日召开业绩说明会，华创证券、华福证券等多家机构参与
以岭药业可持续发展之路：守正创新，良药为民
证券之星 · 04-28
以岭药业可持续发展之路：守正创新，良药为民
图解以岭药业一季报：第一季度单季净利润同比减74.73%
证券之星 · 04-27
图解以岭药业一季报：第一季度单季净利润同比减74.73%
以岭药业(002603.SZ)发一季度业绩，净利润3.04亿元，同比减少74.73%
智通财经网 · 04-26
以岭药业(002603.SZ)发一季度业绩，净利润3.04亿元，同比减少74.73%
加载更多
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司是一家主要致力于专利创新中药的研发、生产和销售。公司拥有通过GMP认证的胶囊、片剂、颗粒剂、针剂生产线,以及通过欧盟认证的化学药制剂车间。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15.31,"timestamp":1719990183000,"preClose":15.44,"halted":0,"volume":7380043,"delay":0,"floatShares":1377000000,"shares":1671000000,"eps":0.2717,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.13,"latestTime":"07-03 15:00:00","open":15.44,"high":15.47,"low":15.18,"amount":113000000,"amplitude":0.0188,"askPrice":15.32,"askSize":329,"bidPrice":15.31,"bidSize":90,"shortable":0,"etf":0,"ttmEps":0.2717,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"adjPreClose":15.44,"symbolType":"stock","openAndCloseTimeList":[[1719970200000,1719977400000],[1719982800000,1719990000000]],"highLimit":16.98,"lowLimit":13.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"pbRate":2.19,"roa":"--","roe":"2.62%","epsLYR":0.8095,"committee":-0.105892,"marketValue":25578000000,"floatMarketCap":21078000000,"peRate":56.348915,"changeRate":-0.0084,"turnoverRate":0.0054,"status":1},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2445757280","title":"以岭药业（002603）股东吴相君质押80万股，占总股本0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445757280","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445757280?lang=zh_cn&edition=full","pubTime":"2024-06-21 21:25","pubTimestamp":1718976325,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业6月21日公开信息显示，股东吴相君向中信证券股份有限公司合计质押80.0万股，占总股本0.05%。质押详情见下表：截止本公告日，股东以岭医药科技有限公司已累计质押股份4900.0万股，占其持股总数的9.3%，股东吴相君已累计质押股份1216.0万股，占其持股总数的3.5%，股东吴瑞已累计质押股份726.0万股，占其持股总数的18.57%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100051020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","002603","BK0042","BK0046","BK0239","BK0188"],"gpt_icon":0},{"id":"2445758725","title":"以岭药业：我们会及时反馈至公司管理层及电商部门参考","url":"https://stock-news.laohu8.com/highlight/detail?id=2445758725","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445758725?lang=zh_cn&edition=full","pubTime":"2024-06-21 19:01","pubTimestamp":1718967719,"startTime":"0","endTime":"0","summary":"动物实验是评估药物疗效和安全性的重要环节，为临床试验提","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100043779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0042","002603","BK0046","BK0097"],"gpt_icon":0},{"id":"2444136927","title":"以岭药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2444136927","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444136927?lang=zh_cn&edition=full","pubTime":"2024-06-17 13:56","pubTimestamp":1718603788,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日石家庄以岭药业股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来石家庄以岭药业股份有限公司新申请注册商标30件，截止目前公司共持有注册商标1140件，另有187件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700010800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0188","BK0042","BK0097","BK0239"],"gpt_icon":0},{"id":"2443505274","title":"以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2443505274","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443505274?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:31","pubTimestamp":1718274668,"startTime":"0","endTime":"0","summary":"以岭药业公告，公司全资子公司北京以岭药业有限公司近日收到国家药品监督管理局下发的《受理通知书》，由北京以岭提交的“柴黄利胆胶囊”新药注册申请已获正式受理。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300034668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0188","BK0046","002603","BK0097"],"gpt_icon":0},{"id":"2443032265","title":"以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2443032265","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443032265?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:21","pubTimestamp":1718274061,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司全资子公司北京以岭药业有限公司(简称“北京以岭”)收到国家药品监督管理局下发的《受理通知书》，由北京以岭提交的“柴黄利胆胶囊”新药注册申请已获正式受理。柴黄利胆胶囊是公司自主研制的中药创新药，其功能主治为：清热利湿，疏肝利胆，和胃止痛。用于慢性胆囊炎肝胆湿热、胃失和降证，症见右上腹胀痛或不适，晨起口苦，口干咽干，脘腹胀满，或伴有恶心欲吐，厌食油腻，纳呆，嗳气，身重困倦，烦躁易怒，胸闷不舒，小便黄赤，大便不爽或秘结，舌质红，苔黄腻，脉弦滑数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603","BK0239","BK0097","BK0046","BK0188","BK0042"],"gpt_icon":0},{"id":"2441218599","title":"重磅！以岭药业创新中药治疗早衰研究取得重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2441218599","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441218599?lang=zh_cn&edition=full","pubTime":"2024-06-05 11:20","pubTimestamp":1717557629,"startTime":"0","endTime":"0","summary":"“八子补肾胶囊治疗早衰的随机、双盲、多中心、安慰剂对照临床研究”论文在《植物医学》的发表，阐释了中医药抗衰老的优势，为以岭药业创新中药八子补肾胶囊作为治疗早衰症状的药物提供了临床证据，为医学界治疗早衰研究开辟了新思路！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024060500021944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0097","002603","BK0239","BK0042"],"gpt_icon":0},{"id":"2440151894","title":"以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2440151894","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440151894?lang=zh_cn&edition=full","pubTime":"2024-06-02 01:02","pubTimestamp":1717261326,"startTime":"0","endTime":"0","summary":"证券之星消息，近日以岭药业（002603）新注册了《以岭药业招标采购平台V1.0》项目的软件著作权。今年以来以岭药业新注册软件著作权1个。结合公司2023年年报财务数据，2023年公司在研发方面投入了8.53亿元，同比减17.33%。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060200000072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","002603","BK0097","BK0046","BK0239"],"gpt_icon":0},{"id":"2439566167","title":"以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2439566167","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439566167?lang=zh_cn&edition=full","pubTime":"2024-05-29 10:43","pubTimestamp":1716950629,"startTime":"0","endTime":"0","summary":"会上发布了2024年优质药材“三无一全”基地品种，以岭药业泽泻上榜。以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单中药材基地共建共享交流大会是由国医大师、中国工程院院士张伯礼等专家以及各知名中药企业共同发起的“国家中药材标准化与质量评估创新联盟”主办的行业交流盛会。自2013年以来，中药材基地共建共享交流大会已举办十届。该基地所产药材全部用于中药芪苈强心胶囊的生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024052900019564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0188","BK0042","BK0097","BK0239"],"gpt_icon":0},{"id":"2437094364","title":"[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2437094364","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437094364?lang=zh_cn&edition=full","pubTime":"2024-05-22 09:05","pubTimestamp":1716339904,"startTime":"0","endTime":"0","summary":"交流会上，问及研发成果，以岭药业董事长兼总经理吴相君表示，公司形成了独具优势的以络病理论指导临床重大疾病治疗研究，络病理论创新带动专利新药研发的科技核心竞争力，遵循“以临床实践为基础，以理论假说为指导，以治疗方药为依托，以临床疗效为标准”的创新中药研发模式，开展复方中药、组分中药、单体中药多渠道研发，建立了具有自主知识产权的新药研发体系，科技创新能力居中药行业前列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024052200013670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0188","BK0046","002603","BK0097"],"gpt_icon":0},{"id":"2436376519","title":"以岭药业（002603）5月16日主力资金净卖出5918.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436376519","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436376519?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:21","pubTimestamp":1715908892,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，以岭药业报收于19.49元，下跌1.76%，换手率1.36%，成交量18.75万手，成交额3.69亿元。近5日资金流向一览见下表：以岭药业融资融券信息显示，融资方面，当日融资买入2787.47万元，融资偿还2584.69万元，融资净买入202.78万元，连续3日净买入累计1014.23万元。以岭药业主营业务：专利创新中药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0042","002603","BK0046","BK0097"],"gpt_icon":0},{"id":"2435119591","title":"世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2435119591","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435119591?lang=zh_cn&edition=full","pubTime":"2024-05-14 19:11","pubTimestamp":1715685117,"startTime":"0","endTime":"0","summary":"在5月10日的2024世界品牌莫干山大会系列分论坛——品牌信用建设论坛上，以岭药业报送的《继承创新、造福人类——以岭药业践行ESG理念 打通中医药可持续、高质量发展“经络”》案例入选“大健康领域品牌信用建设典型案例”。在大会“新质健康 慧鉴未来”健康中国品牌发展论坛，以岭药业董事、副总经理张蕴龄作题为《创新引领开启中医药发展新篇章》的主旨发言。以岭药业在微血管病变防治重大慢病研究中取得系列科研成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024051400028665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0097","BK0239","BK0188","BK0042"],"gpt_icon":0},{"id":"2435399497","title":"向世界讲好中医药故事，以岭药业荣获“品牌创新先锋企业”称号","url":"https://stock-news.laohu8.com/highlight/detail?id=2435399497","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435399497?lang=zh_cn&edition=full","pubTime":"2024-05-13 10:30","pubTimestamp":1715567427,"startTime":"0","endTime":"0","summary":"得益于优秀的品牌建设和国际传播实践，以岭药业入选参考消息报社《中国企业海外传播力分析报告》优秀案例，并获得“品牌创新先锋企业”称号。以岭药业荣获“品牌创新先锋企业”称号该报告旨在加强中国企业海外传播力研究，助力中国企业在“走出去”的同时“讲好中国故事”，为塑造中国良好国际形象做出贡献。在构建人类卫生健康共同体的背景下，以岭药业完成了从“中国产品”向“中国品牌”的升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024051300005633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0097","002603","BK0188","BK0046"],"gpt_icon":0},{"id":"2434038546","title":"以岭药业：创新中药 助力构建人类卫生健康共同体","url":"https://stock-news.laohu8.com/highlight/detail?id=2434038546","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434038546?lang=zh_cn&edition=full","pubTime":"2024-05-09 10:01","pubTimestamp":1715220080,"startTime":"0","endTime":"0","summary":"作为创新中药龙头企业，石家庄以岭药业股份有限公司30余年始终秉承“继承创新、造福人类”的企业宗旨，将传统中医药智慧与现代科技相结合，以中医络病理论创新构建核心竞争力，按照国际标准对照，提供循证医学证据，研发并在世界各地上市了14个创新专利中药，覆盖多个重大疾病领域，开辟了一条独具特色的中医药走向世界之路，助力构建人类卫生健康共同体。以岭药业生产的芪苈强心胶囊成为焦点之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024050900017776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0042","002603","BK0046","BK0097"],"gpt_icon":0},{"id":"2433741251","title":"以岭药业：后续如有达到信披标准的事项，公司会积极履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2433741251","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433741251?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:01","pubTimestamp":1715166077,"startTime":"0","endTime":"0","summary":"以岭药业董秘：投资者您好，公司2023年年度报告中，公司财务数据对应的期间均为2023年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800034027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0097","BK0239","BK0188","BK0042","002603"],"gpt_icon":0},{"id":"2431393402","title":"以岭药业获信达证券增持评级，推动新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393402","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431393402?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:24","pubTimestamp":1714465466,"startTime":"0","endTime":"0","summary":"4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。信达证券指出，以岭药业其他专利产品销售保持稳定增长，并且在心脑血管和健康产品研发领域取得进展。展望未来，信达证券看好以岭药业在中药、化生药两大核心板块新药研发所带来的业绩增长潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002603","601059"],"gpt_icon":0},{"id":"2431738042","title":"以岭药业非呼吸系统类产品营收创历史新高 中医药临床循证研究筑牢科技核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2431738042","media":"新浪证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431738042?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:53","pubTimestamp":1714355580,"startTime":"0","endTime":"0","summary":" 4月26日晚间，以岭药业发布2023年年报。年报显示，在2022年高基数以及呼吸系统用药市场需求回归正常区间的背景下，公司业绩出现回调但整体幅度较小，报告期内仍实现营业收入103.18亿元，牢牢站稳百亿营收大关，展示出了较强的业绩韧性。从更长的时间跨度来看，2023年营收额相较于疫情前2019年的全年营收58.25亿元增幅显著，公司已整体步入新的发展阶段。非呼吸系统类产品营收总额为70.13亿元，同样创下历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/med/2024-04-29/doc-inatncei1566571.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/med/2024-04-29/doc-inatncei1566571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002603"],"gpt_icon":0},{"id":"2430030771","title":"以岭药业：4月28日召开业绩说明会，华创证券、华福证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2430030771","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430030771?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:56","pubTimestamp":1714301770,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月28日以岭药业发布公告称公司于2024年4月28日召开业绩说明会，华创证券、华福证券、招商证券、民生证券、东北证券、中泰证券、国投证券、浙商证券、平安证券、信达证券、中邮证券、国盛证券、山西证券、西部证券、投资机构、海通证券、华泰证券、建投证券、兴业证券、中信证券、华安证券、国海证券参与。以岭药业主营业务：专利创新中药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800007488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0097","161027","BK0239","BK0188","BK0042"],"gpt_icon":0},{"id":"2430608759","title":"以岭药业可持续发展之路：守正创新，良药为民","url":"https://stock-news.laohu8.com/highlight/detail?id=2430608759","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430608759?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:46","pubTimestamp":1714290415,"startTime":"0","endTime":"0","summary":"以岭药业作为中药创新药龙头公司，承担着中医药传承发展的重任。以岭药业保持高强度的研发投入，2023年研发投入总额在已公布数据的中医药上市公司中排名第二，研发投入占营业收入的比例排名第五。过去五年，以岭药业研发投入持续增长，累计投入接近40亿元。2023年10月，以岭药业创新中药通络明目胶囊获得国家药品监督管理局批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024042800003265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0097","BK0239","BK0188","BK0042","002603"],"gpt_icon":0},{"id":"2430845427","title":"图解以岭药业一季报：第一季度单季净利润同比减74.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430845427","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430845427?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:09","pubTimestamp":1714154991,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业2024年一季报显示，公司主营收入25.23亿元，同比下降35.89%；归母净利润3.04亿元，同比下降74.73%；扣非净利润2.92亿元，同比下降75.18%；负债率31.46%，投资收益381.46万元，财务费用843.57万元，毛利率51.48%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700003756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"gpt_icon":0},{"id":"2430274313","title":"以岭药业(002603.SZ)发一季度业绩，净利润3.04亿元，同比减少74.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430274313","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430274313?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:05","pubTimestamp":1714136710,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布2024年第一季度报告，营业收入25.23亿元，同比减少35.89%。归属于上市公司股东的净利润3.04亿元，同比减少74.73%。归属于上市公司股东的扣除非经常性损益的净利润2.92亿元，同比减少75.18%。基本每股收益0.1819元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002603"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":-0.1498},{"period":"3month","weight":-0.2383},{"period":"6month","weight":-0.3382},{"period":"1year","weight":-0.3891},{"period":"ytd","weight":-0.3307}],"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","perCapita":"7027股","boardName":"医药制造业","registeredCapital":"167070万元","compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.0236},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":0.0074}],"survey":" 石家庄以岭药业股份有限公司是一家主要致力于专利创新中药的研发、生产和销售。公司拥有通过GMP认证的胶囊、片剂、颗粒剂、针剂生产线,以及通过欧盟认证的化学药制剂车间。","serverTime":1720013504371,"listedPrice":34.56,"stockholders":"195905人(较上一季度减少8.55%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}